You can buy or sell IDYA and other stocks, options, and ETFs commission-free!
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA. The listed name for IDYA is IDEAYA Biosciences, Inc. Common Stock.
Yujiro S. Hata
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 24, Pre-Market